Content area

|
|

Metformin kan nedsætte risikoen for kolorektalcancer

Forfatter(e)
Tina Fransgård & Ismail Gögenur Kirurgisk Forskningsenhed, Kirurgisk Afdeling, Køge Sygehus Ugeskr Læger 2015;177:V12140659
Reference: 
Ugeskr Læger 2015;177:V12140659
Blad nummer: 
Sidetal: 
2-5
Metformin can reduce the risk of colorectal cancer
Diabetes mellitus (DM) is an established, independent risk factor for colorectal cancer (CRC). Metformin is the first drug of choice for type 2 DM. Several studies have shown a decreased risk of developing CRC in patients with metformin-treated DM, compared with patients with diabetes not treated with metformin. An increased overall survival and CRC-specific survival in patients with CRC and metformin-treated DM has still not been substantially proven. Further studies are needed before a conclusion can be made whether metformin should be used in the treatment of CRC.
Du skal være logget ind for at læse denne artikel
Log ind

Right side

af Eva Bjerre Søndergaard | 30/11
4 kommentarer
af Ulla Hørding | 30/11
2 kommentarer
af Hans Petter Hougen | 29/11
2 kommentarer
af Thorkil Poulsen | 29/11
1 Kommentar
af Erik Sloth | 22/11
1 Kommentar
af Frank Bang Nissen | 21/11
3 kommentarer